In our recent studies [29, 30], we have further demonstrated the proof of concept that strongly support the clinical development of CD40-targeting therapeutic vaccines for HPV16-associated cancers using our prototype vaccine, anti-CD40-HPV16.E6/7 protein. This evidence concerns the gene CD40 and cancer.